Form 4: Enliven Therapeutics' Chief Scientific Officer Sells Shares
SEC Form 4 Filing
Joseph P. Lyssikatos, Chief Scientific Officer of Enliven Therapeutics, sold shares of common stock on July 29, 2024, under a pre-arranged trading plan.
Summary
- On July 29, 2024, Joseph P. Lyssikatos, the Chief Scientific Officer of Enliven Therapeutics, sold shares of the company's common stock.
- The sales were executed in multiple trades at varying prices.
- A total of 11,797 shares were sold at a weighted average price of $26.6855.
- An additional 203 shares were sold at a weighted average price of $27.4333.
- These transactions were conducted under a Rule 10b5-1 trading plan adopted on June 26, 2023.
- Following the reported transactions, Lyssikatos indirectly owns 1,093,035 shares through The Lyssikatos Revocable Trust 12/15/2011, for which he serves as trustee.
Sentiment
Score: 5
Explanation: The document is a standard SEC Form 4 filing, indicating insider trading activity. The sentiment is neutral as it simply reports transactions without expressing any opinion or outlook.
Industry Context
Insider selling can sometimes be interpreted negatively by the market, but sales under pre-arranged trading plans are common and often don't signal a lack of confidence in the company.
Stakeholder Impact
- Shareholders may react to the news of insider selling, although the existence of a pre-arranged trading plan may mitigate concerns.
Key Dates
| Date | Description |
|---|---|
| 12/15/2011 | Date of The Lyssikatos Revocable Trust |
| 06/26/2023 | Date the Rule 10b5-1 trading plan was adopted |
| 07/29/2024 | Date of the stock sale transactions |
| 07/31/2024 | Date of the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.